脑室内SHH抑制在SHH型髓母细胞瘤小鼠模型中有效并预防全身副作用
该研究在Math1-cre::Ptch1Fl/Fl婴儿髓母细胞瘤小鼠模型中评估脑室内给予Vismodegib的疗效与全身副作用。结果显示脑室内治疗在完成治疗后仅2天即导致完全或部分肿瘤缓解,并以剂量依赖方式显著改善无症状生存,同时预防了骨骼畸形等全身副作用。作者结论认为脑室内应用SHH通路抑制剂结合了特异性治疗剂与精准给药的优势,可能成为SHH型髓母细胞瘤患者靶向治疗的新途径。
要点
- 脑室内Vismodegib在Math1-cre::Ptch1Fl/Fl小鼠中完成治疗后仅2天即导致完全或部分肿瘤缓解。
- 脑室内治疗以剂量依赖方式显著改善无症状生存。
- 脑室内给药预防了全身给药所致的解剖或组织学骨骼畸形等全身副作用。
核心结论
- 作者结论认为脑室内应用SHH通路抑制剂结合了特异性治疗剂与精准给药的优势,可能成为SHH型髓母细胞瘤患者靶向治疗的新途径。
研究设计与样本
- 研究在Math1-cre::Ptch1Fl/Fl婴儿髓母细胞瘤小鼠模型中给予脑室内Vismodegib,以评估对肿瘤生长和全身副作用的效果。
主要发现
- 脑室内Vismodegib治疗Math1-cre::Ptch1Fl/Fl小鼠在完成治疗后仅2天导致完全或部分肿瘤缓解。
- 脑室内治疗以剂量依赖方式显著改善无症状生存。
- 脑室内给药预防了解剖或组织学骨骼畸形形式的全身副作用。
关键数值与推荐
- 全身应用Vismodegib后婴儿小鼠和儿童出现不可逆的过早骺板生长板融合,限制了其在儿科患者中的应用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medulloblastoma (MB) is the most common malignant brain tumor in children and requires intensive multimodal therapy. Long-term survival is still dissatisfying and, most importantly, survivors frequently suffer from severe treatment-associated morbidities. The sonic hedgehog pathway (SHH) in SHH MB provides a promising target for specific therapeutic agents. The small molecule Vismodegib allosterically inhibits SMO, the main upstream activator of SHH. Vismodegib has proven effective in the treatment of MB in mice and in clinical studies. However, due to irreversible premature epiphyseal growth plate fusions after systemic application to infant mice and children, its implementation to pediatric patients has been limited. Intraventricular Vismodegib application might provide a promising novel treatment strategy for pediatric medulloblastoma patients. METHODS: Infant medulloblastoma-bearing Math1-cre::Ptch1Fl/Fl mice were treated with intraventricular Vismodegib in order to evaluate efficacy on tumor growth and systemic side effects. RESULTS: We show that intraventricular Vismodegib treatment of Math1-cre::Ptch1Fl/Fl mice leads to complete or partial tumor remission only 2 days after completed treatment. Intraventricular treatment also significantly improved symptom-free survival in a dose-dependent manner. At the same time, intraventricular application prevented systemic side effects in the form of anatomical or histological bone deformities. CONCLUSIONS: We conclude that intraventricular application of a SHH pathway inhibitor combines the advantages of a specific treatment agent with precise drug delivery and might evolve as a promising new way of targeted treatment for SHH MB patients.
引用
- Kresbach C, Holst L, Schoof M, et al. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects. Neuro Oncol. 2024. PMID: 37767814. doi:10.1093/neuonc/noad191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。